Literature DB >> 20604816

Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia.

Karel Odrazka1, Martin Dolezel, Jaroslav Vanasek, Miloslava Vaculikova, Milan Zouhar, Jana Sefrova, Petr Paluska, Milan Vosmik, Tereza Kohlova, Iveta Kolarova, Pavel Navratil, Milos Brodak, Petr Prosvic, Petr Hoffmann.   

Abstract

OBJECTIVES: To retrospectively compare late toxicity of conventional-dose three-dimensional conformal radiation therapy (3D-CRT) and high-dose intensity-modulated radiation therapy (IMRT) for prostate cancer.
METHODS: A total of 340 patients with T1-3 prostate cancer were treated with 3D-CRT (n = 228) and IMRT (n = 112). The median follow-up time was 5.9 years and 3.0 years, respectively. The prescription dose was 70 Gy for 3D-CRT and 78 Gy for IMRT. Late gastrointestinal (GI) and genitourinary (GU) toxicities were graded according to the Fox Chase modification of the Radiation Therapy Oncology Group and Late Effects Normal Tissue Task Force criteria.
RESULTS: There was no difference between 3D-CRT and IMRT in the incidence of GI and GU toxicity at 3 years. On multivariate analysis, transurethral resection of prostate/open transvesical prostatectomy (TURP/TVPE) for benign prostatic hyperplasia, carried out before radiotherapy, significantly increased the risk of Grade >or=2 GU toxicity (risk ratio 1.88). Among patients who experienced TURP/TVPE, the 5-year actuarial likelihood of Grade 2-3 urinary incontinence was 23%, compared with 9% for those without prostate surgery (P = 0.01).
CONCLUSIONS: Tolerance of 3D-CRT and IMRT was similar, despite the use of high radiation dose with IMRT. Previous TURP/TVPE increased the risk of GU toxicity.

Entities:  

Mesh:

Year:  2010        PMID: 20604816     DOI: 10.1111/j.1442-2042.2010.02592.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.

Authors:  Justin E Bekelman; Nandita Mitra; Jason Efstathiou; Kaijun Liao; Robert Sunderland; Deborah N Yeboa; Katrina Armstrong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-16       Impact factor: 7.038

2.  Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last?

Authors:  Sung Kim; Dirk F Moore; Weichung Shih; Yong Lin; Hui Li; Yu-Hsuan Shao; Shunhua Shen; Grace L Lu-Yao
Journal:  J Urol       Date:  2012-11-16       Impact factor: 7.450

3.  The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures.

Authors:  Ting Yu; Qiongwen Zhang; Tianying Zheng; Huashan Shi; Yang Liu; Shijian Feng; Meiqin Hao; Lei Ye; Xueqian Wu; Cheng Yang
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

4.  Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.

Authors:  Sarah L Kerns; Laura Fachal; Leila Dorling; Gillian C Barnett; Andrea Baran; Derick R Peterson; Michelle Hollenberg; Ke Hao; Antonio Di Narzo; Mehmet Eren Ahsen; Gaurav Pandey; Søren M Bentzen; Michelle Janelsins; Rebecca M Elliott; Paul D P Pharoah; Neil G Burnet; David P Dearnaley; Sarah L Gulliford; Emma Hall; Matthew R Sydes; Miguel E Aguado-Barrera; Antonio Gómez-Caamaño; Ana M Carballo; Paula Peleteiro; Ramón Lobato-Busto; Richard Stock; Nelson N Stone; Harry Ostrer; Nawaid Usmani; Sandeep Singhal; Hiroshi Tsuji; Takashi Imai; Shiro Saito; Rosalind Eeles; Kim DeRuyck; Matthew Parliament; Alison M Dunning; Ana Vega; Barry S Rosenstein; Catharine M L West
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

5.  Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Aurore Goineau; Virginie Marchand; Jérome Rigaud; Sylvain Bourdin; Emmanuel Rio; Loic Campion; Angélique Bonnaud-Antignac; Marc-André Mahé; Stéphane Supiot
Journal:  Radiat Oncol       Date:  2013-03-06       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.